Income Statement (TTM)
PharmaCielo Ltd. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 4 | 4 | 5 | 5 | 3 | 3 | 2 | 3 | 3 |
| Change (%) | 9.23 | 6.06 | -27.95 | 22.64 | -21.81 | 27.04 | 67.70 | -0.24 | 28.41 | -7.81 | -40.04 | -4.21 | -42.38 | 60.33 | 34.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 8 | 9 | 9 | 10 | 8 | 6 | 6 | 6 | 4 | 4 | 4 | 4 | 4 | 2 | 3 | 3 |
| Change (%) | 14.40 | 8.36 | 3.59 | -12.86 | -27.67 | -7.08 | 0.53 | -31.38 | 5.21 | 0.45 | -8.92 | -2.13 | -37.48 | 11.10 | 7.14 | |
| % of Revenue | 311.04 | 325.77 | 332.84 | 478.50 | 339.99 | 314.49 | 230.04 | 137.90 | 94.85 | 77.71 | 84.67 | 128.61 | 131.41 | 142.59 | 98.80 | 79.00 |
| Gross Operating Profit | -5 | -6 | -7 | -8 | -6 | -4 | -3 | -2 | 0 | 1 | 1 | -1 | -1 | -1 | 0 | 1 |
| Change (%) | 16.86 | 9.38 | 17.13 | -22.24 | -30.12 | -22.98 | -51.12 | -113.55 | 456.00 | -36.61 | -192.50 | 6.25 | -6.43 | -104.51 | 2,251.60 | |
| % of Revenue | -211.04 | -225.77 | -232.84 | -378.50 | -239.99 | -214.49 | -130.04 | -37.90 | 5.15 | 22.29 | 15.33 | -23.65 | -26.23 | -42.59 | 1.20 | 21.00 |
| SG&A | 29 | 34 | 33 | 31 | 31 | 20 | 17 | 15 | 12 | 12 | 12 | 11 | 10 | 6 | 6 | 5 |
| Change (%) | 19.32 | -3.63 | -5.81 | -0.23 | -37.16 | -13.48 | -13.56 | -18.20 | -1.35 | -2.35 | -6.90 | -10.54 | -33.81 | -10.51 | -4.71 | |
| % of Revenue | 1,185.93 | 1,295.51 | 1,177.15 | 1,538.82 | 1,251.78 | 1,006.01 | 685.13 | 353.12 | 289.56 | 222.45 | 235.62 | 365.80 | 341.64 | 392.45 | 219.04 | 155.76 |
| R&D | ||||||||||||||||
| Change (%) | ||||||||||||||||
| % of Revenue | ||||||||||||||||
| OpEx | 38 | 45 | 44 | 42 | 41 | 27 | 24 | 22 | 17 | 16 | 16 | 14 | 13 | 9 | 9 | 8 |
| Change (%) | 16.81 | -0.86 | -4.33 | -3.19 | -33.93 | -12.34 | -7.57 | -20.22 | -6.11 | -2.27 | -11.67 | -10.65 | -29.01 | -4.93 | -4.52 | |
| % of Revenue | 1,568.24 | 1,677.02 | 1,567.52 | 2,081.33 | 1,642.99 | 1,388.29 | 957.91 | 527.94 | 422.20 | 308.69 | 327.24 | 482.05 | 449.63 | 553.99 | 328.48 | 234.06 |
| Operating Income | -36 | -42 | -41 | -40 | -38 | -25 | -21 | -18 | -13 | -11 | -11 | -11 | -10 | -7 | -6 | -5 |
| Change (%) | 17.32 | -1.30 | -2.72 | -4.49 | -34.71 | -15.40 | -16.35 | -24.89 | -16.83 | 0.39 | 0.42 | -12.74 | -24.55 | -19.31 | -21.37 | |
| % of Revenue | -1,468.24 | -1,577.02 | -1,467.52 | -1,981.33 | -1,542.99 | -1,288.29 | -857.91 | -427.94 | -322.20 | -208.69 | -227.24 | -380.56 | -346.69 | -453.99 | -228.48 | -134.06 |
| Interest Expense | -0 | -0 | -0 | -0 | -1 | -0 | -0 | -1 | -0 | -1 | -2 | |||||
| Change (%) | -42.99 | -0.00 | -0.00 | 264.73 | 103.52 | 271.40 | -56.74 | 75.77 | 225.57 | |||||||
| % of Revenue | -14.01 | -10.21 | -8.04 | -4.79 | -17.53 | -2.47 | -8.38 | -32.50 | -24.40 | -26.75 | -64.99 | |||||
| Net Income | -36 | -44 | -44 | -43 | -42 | -27 | -23 | -19 | -16 | -15 | -15 | -15 | -13 | -14 | -14 | -9 |
| Change (%) | 20.69 | 0.51 | -1.13 | -2.40 | -37.25 | -13.63 | -16.12 | -18.54 | -7.62 | 4.46 | 0.45 | -15.84 | 10.37 | -0.83 | -34.85 | |
| % of Revenue | -1,492.20 | -1,648.73 | -1,562.47 | -2,144.01 | -1,706.22 | -1,369.14 | -930.82 | -465.57 | -380.13 | -273.45 | -309.85 | -519.04 | -456.04 | -873.57 | -540.35 | -262.70 |
Source: Capital IQ
